• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.一种用于评估抗干扰素β抗体临床相关性的灵敏放射免疫沉淀测定法。
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1236-9. doi: 10.1136/jnnp.74.9.1236.
2
Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.对多发性硬化症患者进行干扰素-β（IFN-β）抗体的系列免疫沉淀试验。
Eur Cytokine Netw. 2003 Jul-Sep;14(3):154-7.
3
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).多发性硬化症中抗干扰素β-1a中和抗体的发生率及意义。多发性硬化症协作研究组（MSCRG）。
Neurology. 1998 May;50(5):1266-72. doi: 10.1212/wnl.50.5.1266.
4
Optimising MS disease-modifying therapies: antibodies in perspective.优化多发性硬化症疾病修正疗法：抗体的视角
J Neurol. 2004 Sep;251 Suppl 5:v30-v35. doi: 10.1007/s00415-004-1505-x.
5
Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.将干扰素-β中和抗体测定法纳入常规临床实践。
Mult Scler. 2011 Nov;17(11):1333-40. doi: 10.1177/1352458511412654. Epub 2011 Jun 17.
6
Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.对接受β-1a干扰素或β-1b干扰素治疗的复发缓解型多发性硬化症患者中干扰素（IFN）中和抗体的特异性和发生率的进一步研究。
J Neurol Sci. 1999 Oct 15;168(2):131-6. doi: 10.1016/s0022-510x(99)00185-9.
7
Neutralizing antibodies to interferon.针对干扰素的中和抗体。
Neurology. 2007 Jun 12;68(24 Suppl 4):S16-22. doi: 10.1212/01.wnl.0000277705.63813.84.
8
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.多发性硬化症患者中干扰素-β 中和抗体的早期检测：结合抗体可预测中和抗体的产生。
Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5.
9
Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients.两组复发缓解型多发性硬化症患者中抗β-干扰素结合抗体和中和抗体的研究
J Neurol. 2001 May;248(5):383-8. doi: 10.1007/s004150170178.
10
Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?针对干扰素-β的体外中和抗体在多发性硬化症中是否总是对治疗效果不利？
Mult Scler. 2007 Jun;13(5):616-21. doi: 10.1177/1352458506072344. Epub 2007 Feb 9.

引用本文的文献

1
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.抗多发性硬化症生物治疗药物的抗体。
CNS Drugs. 2022 Jun;36(6):569-589. doi: 10.1007/s40263-022-00920-6. Epub 2022 May 19.
2
Low Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series.症状波动小可能延迟重症肌无力的诊断：病例系列报道
Neurol Ther. 2022 Mar;11(1):481-487. doi: 10.1007/s40120-021-00312-w. Epub 2021 Dec 18.
3
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.多发性硬化症中干扰素-β中和抗体的临床检测。
Ther Adv Neurol Disord. 2013 Jan;6(1):3-17. doi: 10.1177/1756285612469264.
4
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24.

本文引用的文献

1
Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.接受干扰素β-1a和干扰素β-1b治疗的多发性硬化症患者体内的干扰素β（INF-β）抗体。患病率、动力学、交叉反应性以及体内增强干扰素β免疫原性的因素。
Eur Cytokine Netw. 2001 Mar;12(1):56-61.
2
Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.中和性及结合性抗β干扰素（IFN-β）抗体。多发性硬化症中干扰素β-1a与干扰素β-1b治疗的比较。
Eur J Neurol. 2000 Jan;7(1):27-34. doi: 10.1046/j.1468-1331.2000.00002.x.
3
The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.接受β-1b干扰素治疗的多发性硬化症患者体内中和抗体的演变
Neurology. 1999 Apr 12;52(6):1277-9. doi: 10.1212/wnl.52.6.1277.
4
A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.一种用于测定抗β-1b干扰素中和抗体的新型生物测定法。
J Interferon Cytokine Res. 1998 Dec;18(12):1025-30. doi: 10.1089/jir.1998.18.1025.
5
A novel sensitive and selective bioassay for human type I interferons.一种用于人I型干扰素的新型灵敏且具选择性的生物测定法。
J Interferon Cytokine Res. 1998 Dec;18(12):1019-24. doi: 10.1089/jir.1998.18.1019.
6
A radioimmuno-precipitation assay for antibodies to botulinum A.肉毒杆菌A抗体的放射免疫沉淀测定法。
Neurology. 1998 May;50(5):1463-6. doi: 10.1212/wnl.50.5.1463.
7
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).多发性硬化症中抗干扰素β-1a中和抗体的发生率及意义。多发性硬化症协作研究组（MSCRG）。
Neurology. 1998 May;50(5):1266-72. doi: 10.1212/wnl.50.5.1266.

一种用于评估抗干扰素β抗体临床相关性的灵敏放射免疫沉淀测定法。

A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.

作者信息

Lawrence N, Oger J, Aziz T, Palace J, Vincent A

机构信息

Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

出版信息

J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1236-9. doi: 10.1136/jnnp.74.9.1236.

DOI:10.1136/jnnp.74.9.1236
PMID:12933925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1738680/
Abstract

BACKGROUND

Some multiple sclerosis (MS) patients treated with interferon beta (IFN beta) develop antibodies to the drug. Neutralising antibody (NAB) assays for IFN beta are expensive and the clinical relevance of the results has been debated.

OBJECTIVE

To establish a cheap, sensitive, and reliable assay for antibodies to (125)I-IFN beta, and to correlate levels of antibodies with clinical response to IFN beta treatment.

METHODS

We established a radioimmunoprecipitation assay (RIPA) using (125)I-IFN beta. We tested NAB positive sera, healthy control sera, and serial samples of 33 IFN beta-1b treated MS patients from the Vancouver cohort of the Berlex pivotal trial who had a high incidence of NABs.

RESULTS

We found that the RIPA was highly sensitive for the detection of antibodies to IFN beta-1a and -1b, and that there was a strong correlation between reactivity of NAB positive sera for (125)I-IFN beta-1b and for (125)I-IFN beta-1a. The RIPA was more sensitive and consistent than the NAB. Moreover, there was a trend towards poorer MRI outcomes in RIPA positive patients, but not in NAB-positive patients.

CONCLUSIONS

The RIPA assay is sensitive and easy to perform. It should be of value in assessing the clinical impact of IFN beta antibodies, and its use could help target expensive INF beta treatments to those who will respond best.

摘要

背景

一些接受β-干扰素（IFNβ）治疗的多发性硬化症（MS）患者会产生针对该药物的抗体。用于检测IFNβ的中和抗体（NAB）检测方法昂贵，且检测结果的临床相关性一直存在争议。

目的

建立一种廉价、灵敏且可靠的针对（125）I-IFNβ抗体的检测方法，并将抗体水平与IFNβ治疗的临床反应相关联。

方法

我们使用（125）I-IFNβ建立了一种放射免疫沉淀测定法（RIPA）。我们检测了NAB阳性血清、健康对照血清，以及来自Berlex关键试验温哥华队列的33例接受IFNβ-1b治疗的MS患者的系列样本，这些患者中NAB的发生率很高。

结果

我们发现RIPA对检测IFNβ-1a和-1b的抗体具有高度敏感性，并且NAB阳性血清对（125）I-IFNβ-1b和（125）I-IFNβ-1a的反应性之间存在很强的相关性。RIPA比NAB更灵敏且更稳定。此外，RIPA阳性患者的MRI结果有变差的趋势，但NAB阳性患者则没有。

结论

RIPA检测灵敏且易于操作。它在评估IFNβ抗体的临床影响方面应该具有价值，其应用有助于将昂贵的IFNβ治疗靶向那些反应最佳的患者。